Abiopharma

🔍 Travin David Adam (Executive)

Company: PJT Partners Inc. (PJT)

Report Date: 2026-05-06

Detailed Transactions and Holdings:

• Sold 2,748 shares of Class A Common Stock at $152.38 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 2,304.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 252 shares of Class A Common Stock at $152.92 per share (Direct)
  Date: 2026-05-06 | Code: S | equity_swap_involved: false | shares_owned_after: 2,052.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: Represents Class A common stock of the Issuer acquired upon settlement of a restricted stock unit award previously granted to the Reporting Person.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transacations ranging from $151.73 to $152.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $152.74 to $153.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.